Page last updated: 2024-12-06

indenolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Indenolol is a non-selective beta-adrenergic receptor antagonist that was originally developed for the treatment of hypertension and angina. It was synthesized in the 1970s and has been studied for its potential therapeutic effects in a variety of cardiovascular conditions. However, it was ultimately withdrawn from clinical trials due to concerns about its adverse effects. Indenolol is a potent beta-blocker that can inhibit the action of norepinephrine and epinephrine on beta receptors. These receptors are found in the heart, blood vessels, lungs, and other organs. By blocking these receptors, indenolol can slow the heart rate, lower blood pressure, and dilate blood vessels. It is still used in research to study the role of beta-adrenergic receptors in various physiological processes. Indenolol may also be used as a tool to investigate the mechanism of action of other beta-blockers.'

indenolol: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71955
CHEMBL ID153585
SCHEMBL ID79021
MeSH IDM0043879

Synonyms (29)

Synonym
1-(inden-4(or 7)-yloxy)-3-(isopropylamino)-2-propanol
indenololum [inn-latin]
einecs 262-323-5
sch 28316z
1-(4-indenyloxy)-3-isopropylamino-2-propanol
sch 28316 z
indenolol
CHEMBL153585
1-(1h-inden-4-yloxy)-3-(propan-2-ylamino)propan-2-ol
indenolol (inn)
60607-68-3
D08078
106656-86-4
indenolol [inn:ban]
indenololum
unii-3mzm7rww00
3mzm7rww00 ,
8gu15n96i8 ,
unii-8gu15n96i8
4-(2-hydroxy-3-isopropylaminopropoxy)indene
2-propanol, 1-(1h-inden-4-yloxy)-3-((1-methylethyl)amino)-
SCHEMBL79021
4-(3-isopropylamino-2-hydroxypropoxy)indene
MPGBPFMOOXKQRX-UHFFFAOYSA-N
DB08952
Q3797865
1-(1h-inden-4-yloxy)-3-[(1-methylethyl)amino]-2-propanol
DTXSID70866817
AKOS040745868

Research Excerpts

Overview

Indenolol is a nonselective beta-adrenoceptor antagonist. Its sympathomimetic properties have been shown in vitro but not in human beings.

ExcerptReferenceRelevance
"Indenolol is a noncardioselective beta-adrenoceptor blocking drug with partial agonist activity. "( Renal and limb vasodilatation during acute beta-adrenoceptor blockade with indenolol.
Bisi, G; Del Rosso, A; La Cava, G; Masotti, G; Poggesi, L; Sciagra, R, 1995
)
1.96
"Indenolol is a nonselective beta-adrenoceptor antagonist whose sympathomimetic properties have been shown in vitro but not in human beings."( Indenolol, a beta-blocker with partial agonism at vascular beta-adrenoceptors.
Pedrinelli, R; Salvetti, A; Taddei, S, 1989
)
2.44
"Indenolol is a new antihypertensive agent, whose beta 1-adrenoceptor antagonist properties combined with beta 2-adrenoceptor agonist properties have been shown by experimental studies in animals. "( Effect of indenolol treatment on beta-adrenergic receptors of polymorphonucleates in essential hypertension.
Barzizza, F; Corradi, L; Finardi, G; Grandi, A; Groothold, G; Mailland, F; Negri, F; Venco, A, 1986
)
2.12
"Indenolol hydrochloride is a recently introduced antihypertensive substance. "( Computerized echocardiographic study of left ventricular function and cardiodynamic investigation with a new antihypertensive agent (indenolol).
Barzizza, F; Corradi, L; Finardi, G; Grandi, A; Groothold, G; Negri, F; Venco, A, 1985
)
1.92

Actions

ExcerptReferenceRelevance
"Indenolol did not increase BAR number but significantly decreased (P less than 0.01) BAR affinity."( Effect of indenolol treatment on beta-adrenergic receptors of polymorphonucleates in essential hypertension.
Barzizza, F; Corradi, L; Finardi, G; Grandi, A; Groothold, G; Mailland, F; Negri, F; Venco, A, 1986
)
1.39

Bioavailability

ExcerptReferenceRelevance
"Effect of concurrent administration of sucralfate on the bioavailability of indenolol in rats has been investigated."( Effect of sucralfate on the bioavailability of indenolol.
Babhair, SA; Tariq, M, 1984
)
0.75

Dosage Studied

Dose-response curves for both drugs revealed that maximum attenuation of exercise tachycardia and systolic blood pressure were in the same range. The relationship between indenolol (an investigational agent) plasma levels and the drug's effect on blood pressure and heart rate was investigated.

ExcerptRelevanceReference
" On a dosage basis, the order of potency of these compounds is indenolol fluorinated derivative greater than propranolol greater than indenolol greater than nadolol fluorinated derivative greater than nadolol."( Evaluation of the antifibrillatory activity of fluorinated derivatives of indenolol and nadolol in isolated rabbit and rat hearts: comparison with propranolol.
Aboul-Enein, HY; Almotrefi, AA; Premkumar, LS,
)
0.6
"The relationship between indenolol (an investigational agent) plasma levels and the drug's effect on blood pressure and heart rate was investigated after single and repeated once daily administration at two dosage levels (60 mg and 120 mg) in two different groups of patients with first or second stage hypertension, according to the World Health Organization classification."( Indenolol pharmacokinetics and pharmacodynamics after single and repeated daily doses.
Colombo, F; Groothold, G; Guenzati, G; Libretti, A; Mailland, F; Pantarotto, C; Sega, R,
)
1.88
" Dose-response curves for both drugs revealed that maximum attenuation of exercise tachycardia and systolic blood pressure were in the same range but suggested that indenolol induced a greater response in the lower doses."( Dose-response studies of indenolol, a beta adrenoceptor blocker.
Daneshmend, TK; Okupa, FE; Roberts, CJ; Shrosbree, E, 1981
)
0.76
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (35)

TimeframeStudies, This Drug (%)All Drugs %
pre-199028 (80.00)18.7374
1990's5 (14.29)18.2507
2000's1 (2.86)29.6817
2010's1 (2.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.81

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.81 (24.57)
Research Supply Index4.01 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.81)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials14 (35.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other26 (65.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]